cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Arrowhead Pharmaceuticals Inc
20 own
22 watching
Current Price
$24.77
$-0.23
(-0.92%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
4,214.49M
52-Week High
52-Week High
39.83000
52-Week Low
52-Week Low
20.67000
Average Volume
Average Volume
0.71M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization4,214.49M
icon52-Week High39.83000
icon52-Week Low20.67000
iconAverage Volume0.71M
iconDividend Yield--
iconP/E Ratio--
What does the Arrowhead Pharmaceuticals Inc do?
Arrowhead Pharmaceuticals, Inc. develops novel drugs to treat intractable diseases in the United States. Its pre-clinical stage drug candidates include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT to treat liver disease associated with alpha-1 antitrypsin deficiency; ARO-LPA to reduce production of apolipoprotein A; ARO-AMG1, which is developed against an undisclosed genetically validated cardiovascular target; and ARO-F12, a potential treatment for factor 12 mediated diseases, such as hereditary angioedema and thromboembolic disorders. The company also develops ARO-HIF2, a drug candidate for the treatment of clear cell renal cell carcinoma. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreements with Amgen, Inc. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Read More
How much money does Arrowhead Pharmaceuticals Inc make?
News & Events about Arrowhead Pharmaceuticals Inc.
Business Wire
10 months ago
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented updated results from the Phase 2 SEQUOIA clinical study of investigational fazirsiran (TAK-999/ARO-AAT) for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD-LD). The SEQUOIA Phase 2 data are consistent...
TipRanks Financial Blog
1 year ago
In a report released yesterday, Akinori Ueda from Goldman Sachs maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR Research Report), with... In a report released yesterday, Akinori Ueda from Goldman Sachs maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR &#8211...
PR Newswire
1 year ago
Thinking about buying stock in XPO, Virios Therapeutics, Arrowhead Pharmaceuticals, Petros Pharmaceuticals, or Citius Pharmaceuticals? Thinking about buying stock in XPO, Virios Therapeutics, Arrowhead Pharmaceuticals, Petros Pharmaceuticals, or Citius Pharmaceuticals? PR Newswire NEW YORK, April...
Fool.com Headlines
1 year ago
The clinical-stage drug developer is attracting a lot of positive attention from investment bank analysts.Are you looking for stocks that can make dramatic moves in a short amount of time? If so, you'll want to check out Arrowhead Pharmaceuticals (NASDAQ: ARWR). SVB Securities, a subsidiary ofSVB ...
Business Wire
1 year ago
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a Research & Development (R&D) Day on June 1, 2023, beginning at 9 a.m. ET in New York City to discuss progress towards the companys 20 in 25 goal to grow its pipeline of RNAi therapeutics that leverage...
Frequently Asked Questions
Frequently Asked Questions
What is Arrowhead Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Arrowhead Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Arrowhead Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Arrowhead Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Arrowhead Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Arrowhead Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Arrowhead Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Arrowhead Pharmaceuticals Inc?
plus_minus_icon
What percentage is Arrowhead Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Arrowhead Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$24.77
$-0.23
(-0.92%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00